---
document_datetime: 2025-12-17 23:28:06
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/livogiva.html
document_name: livogiva.html
version: success
processing_time: 0.1234513
conversion_datetime: 2025-12-27 23:10:59.764361
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Livogiva

[RSS](/en/individual-human-medicine.xml/67326)

##### Authorised

This medicine is authorised for use in the European Union

teriparatide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Livogiva](#news-on)
- [Product information - with tracked changes](#product-information-with-tracked-changes-81980)
- [Related content](#related-content-910)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Livogiva is a medicine used for the treatment of osteoporosis (a disease that makes bones fragile) in:

- women who have been through the menopause;
- men who are at an increased risk of fractures;
- men and women who are at an increased risk of fractures due to long-term treatment with glucocorticoids (a type of steroid).

Livogiva is a 'biosimilar medicine'. This means that Livogiva is highly similar to another biological medicine (the 'reference medicine') that is already authorised in the EU. The reference medicine for Livogiva is Forsteo.

Livogiva contains the active substance teriparatide.

Expand section

Collapse section

## How is Livogiva used?

Livogiva is available in pre-filled pens as a solution for injection under the skin. The recommended dose is 20 micrograms of Livogiva injected once a day under the skin of the thigh or belly. Patients may inject themselves once they have been trained.

Patients should take calcium and vitamin D supplements if they do not get enough from their diet. Livogiva can be used for up to two years. The two-year course should be given only once during a patient's lifetime.

The medicine can only be obtained with a prescription. For more information about using Livogiva, see the package leaflet or contact your doctor or pharmacist.

## How does Livogiva work?

Osteoporosis happens when not enough new bone grows to replace the bone that is naturally broken down. Gradually, the bones become less dense and more likely to break. In women, osteoporosis is more common after the menopause, when the levels of the female hormone oestrogen fall. Osteoporosis can also occur as a side effect of glucocorticoid treatment in men and women.

The active substance in Livogiva, teriparatide, is identical to part of the human parathyroid hormone. It acts like the hormone to stimulate bone formation by acting on osteoblasts (bone-forming cells). It also increases the absorption of calcium from food and prevents too much calcium being lost in the urine.

## What benefits of Livogiva have been shown in studies?

Laboratory studies comparing Livogiva with Forsteo have shown that the active substance in Livogiva is highly similar to that in Forsteo in terms of structure, purity and biological activity. Studies have also shown that giving Livogiva produces similar levels of the active substance in the body to giving Forsteo.

Because Livogiva is a biosimilar medicine, the studies on effectiveness and safety of teriparatide carried out with Forsteo do not all need to be repeated for Livogiva.

## What are the risks associated with Livogiva?

The safety of Livogiva has been evaluated, and on the basis of all the studies carried out the side effects of the medicine are considered to be comparable to those of the reference medicine Forsteo.

The most common side effect with teriparatide (seen in more than 1 patient in 10) is pain in the arms or legs; nausea (feeling sick), headache and dizziness are also common. For the full list of side effects of Livogiva, see the package leaflet.

Livogiva must not be used in patients who have other bone diseases such as Paget's disease, bone cancer or bone metastases (cancer that has spread to the bone), patients who have had radiation therapy of the skeleton, or patients who have hypercalcaemia (high blood calcium levels), unexplained high levels of alkaline phosphatase (an enzyme that can be a sign of bone disease) or severe kidney disease. Livogiva must not be used during pregnancy or breastfeeding. For the full list of restrictions, see the package leaflet.

## Why is Livogiva authorised in the EU?

The European Medicines Agency decided that, in accordance with EU requirements for biosimilar medicines, Livogiva has a highly similar structure, purity and biological activity to Forsteo and is distributed in the body in the same way.

All these data were considered sufficient to conclude that Livogiva will behave in the same way as Forsteo in terms of effectiveness and safety in its authorised uses. Therefore, the Agency's view was that, as for Forsteo, the benefits of Livogiva outweigh the identified risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Livogiva?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Livogiva have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Livogiva are continuously monitored. Side effects reported with Livogiva are carefully evaluated and any necessary action taken to protect patients.

## Other information about Livogiva

Livogiva received a marketing authorisation valid throughout the EU on 27 August 2020.

Livogiva : EPAR - Medicine overview

Reference Number: EMA/349950/2020

English (EN) (144.53 KB - PDF)

**First published:** 06/01/2021

[View](/en/documents/overview/livogiva-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-418)

български (BG) (165.37 KB - PDF)

**First published:**

06/01/2021

[View](/bg/documents/overview/livogiva-epar-medicine-overview_bg.pdf)

español (ES) (143.47 KB - PDF)

**First published:**

06/01/2021

[View](/es/documents/overview/livogiva-epar-medicine-overview_es.pdf)

čeština (CS) (119.29 KB - PDF)

**First published:**

06/01/2021

[View](/cs/documents/overview/livogiva-epar-medicine-overview_cs.pdf)

dansk (DA) (142.17 KB - PDF)

**First published:**

06/01/2021

[View](/da/documents/overview/livogiva-epar-medicine-overview_da.pdf)

Deutsch (DE) (146.97 KB - PDF)

**First published:**

06/01/2021

[View](/de/documents/overview/livogiva-epar-medicine-overview_de.pdf)

eesti keel (ET) (130.93 KB - PDF)

**First published:**

06/01/2021

[View](/et/documents/overview/livogiva-epar-medicine-overview_et.pdf)

ελληνικά (EL) (165.31 KB - PDF)

**First published:**

06/01/2021

[View](/el/documents/overview/livogiva-epar-medicine-overview_el.pdf)

français (FR) (144.78 KB - PDF)

**First published:**

06/01/2021

[View](/fr/documents/overview/livogiva-epar-medicine-overview_fr.pdf)

hrvatski (HR) (164.14 KB - PDF)

**First published:**

06/01/2021

[View](/hr/documents/overview/livogiva-epar-medicine-overview_hr.pdf)

italiano (IT) (142 KB - PDF)

**First published:**

06/01/2021

[View](/it/documents/overview/livogiva-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (178.77 KB - PDF)

**First published:**

06/01/2021

[View](/lv/documents/overview/livogiva-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (164.31 KB - PDF)

**First published:**

06/01/2021

[View](/lt/documents/overview/livogiva-epar-medicine-overview_lt.pdf)

magyar (HU) (161.46 KB - PDF)

**First published:**

06/01/2021

[View](/hu/documents/overview/livogiva-epar-medicine-overview_hu.pdf)

Malti (MT) (164.76 KB - PDF)

**First published:**

06/01/2021

[View](/mt/documents/overview/livogiva-epar-medicine-overview_mt.pdf)

Nederlands (NL) (143.51 KB - PDF)

**First published:**

06/01/2021

[View](/nl/documents/overview/livogiva-epar-medicine-overview_nl.pdf)

polski (PL) (166.17 KB - PDF)

**First published:**

06/01/2021

[View](/pl/documents/overview/livogiva-epar-medicine-overview_pl.pdf)

português (PT) (143.63 KB - PDF)

**First published:**

06/01/2021

[View](/pt/documents/overview/livogiva-epar-medicine-overview_pt.pdf)

română (RO) (161.33 KB - PDF)

**First published:**

06/01/2021

[View](/ro/documents/overview/livogiva-epar-medicine-overview_ro.pdf)

slovenčina (SK) (163.65 KB - PDF)

**First published:**

06/01/2021

[View](/sk/documents/overview/livogiva-epar-medicine-overview_sk.pdf)

slovenščina (SL) (162.6 KB - PDF)

**First published:**

06/01/2021

[View](/sl/documents/overview/livogiva-epar-medicine-overview_sl.pdf)

Suomi (FI) (140.7 KB - PDF)

**First published:**

06/01/2021

[View](/fi/documents/overview/livogiva-epar-medicine-overview_fi.pdf)

svenska (SV) (142.06 KB - PDF)

**First published:**

06/01/2021

[View](/sv/documents/overview/livogiva-epar-medicine-overview_sv.pdf)

Livogiva : EPAR - Risk management plan

English (EN) (758.87 KB - PDF)

**First published:** 06/01/2021

**Last updated:** 10/12/2025

[View](/en/documents/rmp/livogiva-epar-risk-management-plan_en.pdf)

## Product information

Livogiva : EPAR - Product information

English (EN) (814.08 KB - PDF)

**First published:** 06/01/2021

**Last updated:** 28/11/2025

[View](/en/documents/product-information/livogiva-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-430)

български (BG) (1.08 MB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/bg/documents/product-information/livogiva-epar-product-information_bg.pdf)

español (ES) (786.53 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/es/documents/product-information/livogiva-epar-product-information_es.pdf)

čeština (CS) (951.04 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/cs/documents/product-information/livogiva-epar-product-information_cs.pdf)

dansk (DA) (782.06 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/da/documents/product-information/livogiva-epar-product-information_da.pdf)

Deutsch (DE) (894.94 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/de/documents/product-information/livogiva-epar-product-information_de.pdf)

eesti keel (ET) (787.26 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/et/documents/product-information/livogiva-epar-product-information_et.pdf)

ελληνικά (EL) (894.35 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/el/documents/product-information/livogiva-epar-product-information_el.pdf)

français (FR) (802.17 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/fr/documents/product-information/livogiva-epar-product-information_fr.pdf)

hrvatski (HR) (842.12 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/hr/documents/product-information/livogiva-epar-product-information_hr.pdf)

íslenska (IS) (782.13 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/is/documents/product-information/livogiva-epar-product-information_is.pdf)

italiano (IT) (771.08 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/it/documents/product-information/livogiva-epar-product-information_it.pdf)

latviešu valoda (LV) (829.7 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/lv/documents/product-information/livogiva-epar-product-information_lv.pdf)

lietuvių kalba (LT) (881.12 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/lt/documents/product-information/livogiva-epar-product-information_lt.pdf)

magyar (HU) (858.55 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/hu/documents/product-information/livogiva-epar-product-information_hu.pdf)

Malti (MT) (905.11 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/mt/documents/product-information/livogiva-epar-product-information_mt.pdf)

Nederlands (NL) (878.76 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/nl/documents/product-information/livogiva-epar-product-information_nl.pdf)

norsk (NO) (766.48 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/no/documents/product-information/livogiva-epar-product-information_no.pdf)

polski (PL) (963.22 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/pl/documents/product-information/livogiva-epar-product-information_pl.pdf)

português (PT) (759.07 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/pt/documents/product-information/livogiva-epar-product-information_pt.pdf)

română (RO) (840.31 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/ro/documents/product-information/livogiva-epar-product-information_ro.pdf)

slovenčina (SK) (847.91 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/sk/documents/product-information/livogiva-epar-product-information_sk.pdf)

slovenščina (SL) (846.03 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/sl/documents/product-information/livogiva-epar-product-information_sl.pdf)

Suomi (FI) (759.26 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/fi/documents/product-information/livogiva-epar-product-information_fi.pdf)

svenska (SV) (761.77 KB - PDF)

**First published:**

06/01/2021

**Last updated:**

28/11/2025

[View](/sv/documents/product-information/livogiva-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** R/0015 14/04/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Livogiva : EPAR - All authorised presentations

English (EN) (55.99 KB - PDF)

**First published:** 06/01/2021

[View](/en/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-283)

български (BG) (66.64 KB - PDF)

**First published:**

06/01/2021

[View](/bg/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_bg.pdf)

español (ES) (54.91 KB - PDF)

**First published:**

06/01/2021

[View](/es/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_es.pdf)

čeština (CS) (60.34 KB - PDF)

**First published:**

06/01/2021

[View](/cs/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (52.63 KB - PDF)

**First published:**

06/01/2021

[View](/da/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (51.53 KB - PDF)

**First published:**

06/01/2021

[View](/de/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (53.7 KB - PDF)

**First published:**

06/01/2021

[View](/et/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (63.33 KB - PDF)

**First published:**

06/01/2021

[View](/el/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_el.pdf)

français (FR) (50.13 KB - PDF)

**First published:**

06/01/2021

[View](/fr/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (125.09 KB - PDF)

**First published:**

06/01/2021

[View](/hr/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (57.95 KB - PDF)

**First published:**

06/01/2021

[View](/is/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_is.pdf)

italiano (IT) (53.92 KB - PDF)

**First published:**

06/01/2021

[View](/it/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (65.39 KB - PDF)

**First published:**

06/01/2021

[View](/lv/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (67.56 KB - PDF)

**First published:**

06/01/2021

[View](/lt/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (59.07 KB - PDF)

**First published:**

06/01/2021

[View](/hu/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (67.27 KB - PDF)

**First published:**

06/01/2021

[View](/mt/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (53.74 KB - PDF)

**First published:**

06/01/2021

[View](/nl/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (51.52 KB - PDF)

**First published:**

06/01/2021

[View](/no/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_no.pdf)

polski (PL) (71.87 KB - PDF)

**First published:**

06/01/2021

[View](/pl/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_pl.pdf)

português (PT) (51.4 KB - PDF)

**First published:**

06/01/2021

[View](/pt/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_pt.pdf)

română (RO) (64.51 KB - PDF)

**First published:**

06/01/2021

[View](/ro/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (86.96 KB - PDF)

**First published:**

06/01/2021

[View](/sk/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (66.81 KB - PDF)

**First published:**

06/01/2021

[View](/sl/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (49.46 KB - PDF)

**First published:**

06/01/2021

[View](/fi/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (50.69 KB - PDF)

**First published:**

06/01/2021

[View](/sv/documents/all-authorised-presentations/livogiva-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Livogiva Active substance teriparatide International non-proprietary name (INN) or common name teriparatide Therapeutic area (MeSH) Osteoporosis Anatomical therapeutic chemical (ATC) code H05AA02

### Pharmacotherapeutic group

Calcium homeostasis

### Therapeutic indication

Livogiva is indicated in adults.

Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture. In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures have been demonstrated.

Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture.

## Authorisation details

EMA product number EMEA/H/C/005087

Biosimilar

This is a biosimilar medicine, which is a biological medicine highly similar to another already approved biological medicine called the 'reference medicine'. For more information, see [Biosimilar medicines](/node/68323) .

Marketing authorisation holder

Theramex Ireland Limited

3rd Floor, Kilmore House

Opinion adopted 25/06/2020 Marketing authorisation issued 27/08/2020 Revision 2

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Livogiva : EPAR - Procedural steps taken and scientific Information after authorisation

English (EN) (160.68 KB - PDF)

**First published:** 07/01/2021

**Last updated:** 28/11/2025

[View](/en/documents/procedural-steps-after/livogiva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Livogiva : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/379175/2020

English (EN) (2.61 MB - PDF)

**First published:** 06/01/2021

[View](/en/documents/assessment-report/livogiva-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Livogiva

Adopted

Reference Number: EMA/CHMP/295899/2020

English (EN) (132.07 KB - PDF)

**First published:** 26/06/2020

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-livogiva_en.pdf)

#### News on Livogiva

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 June 2020](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-june-2020) 26/06/2020

#### Product information - with tracked changes

The approved product information for this medicine is available below showing the changes since the previous procedure affecting the product information. The same document without tracked changes is above under 'Product information'.

Livogiva : EPAR - Product information - tracked changes

English (EN) (599.63 KB - DOCX)

**First published:** 10/12/2025

[View](/en/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_en.docx)

[Other languages (24)](#file-language-dropdown-642)

български (BG) (1.13 MB - DOC)

**First published:**

10/12/2025

[View](/bg/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_bg.doc)

español (ES) (684.77 KB - DOCX)

**First published:**

10/12/2025

[View](/es/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_es.docx)

čeština (CS) (799.29 KB - DOCX)

**First published:**

10/12/2025

[View](/cs/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_cs.docx)

dansk (DA) (798.29 KB - DOCX)

**First published:**

10/12/2025

[View](/da/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_da.docx)

Deutsch (DE) (675.3 KB - DOCX)

**First published:**

10/12/2025

[View](/de/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_de.docx)

eesti keel (ET) (763.94 KB - DOCX)

**First published:**

10/12/2025

[View](/et/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_et.docx)

ελληνικά (EL) (719.91 KB - DOCX)

**First published:**

10/12/2025

[View](/el/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_el.docx)

français (FR) (753.91 KB - DOCX)

**First published:**

10/12/2025

[View](/fr/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_fr.docx)

hrvatski (HR) (798.3 KB - DOCX)

**First published:**

10/12/2025

[View](/hr/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_hr.docx)

íslenska (IS) (707.57 KB - DOCX)

**First published:**

10/12/2025

[View](/is/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_is.docx)

italiano (IT) (790.96 KB - DOCX)

**First published:**

10/12/2025

[View](/it/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_it.docx)

latviešu valoda (LV) (688.61 KB - DOCX)

**First published:**

10/12/2025

[View](/lv/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_lv.docx)

lietuvių kalba (LT) (791.79 KB - DOCX)

**First published:**

10/12/2025

[View](/lt/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_lt.docx)

magyar (HU) (812.54 KB - DOCX)

**First published:**

10/12/2025

[View](/hu/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_hu.docx)

Malti (MT) (801.19 KB - DOCX)

**First published:**

10/12/2025

[View](/mt/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_mt.docx)

Nederlands (NL) (771.43 KB - DOCX)

**First published:**

10/12/2025

[View](/nl/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_nl.docx)

norsk (NO) (778.05 KB - DOCX)

**First published:**

10/12/2025

[View](/no/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_no.docx)

polski (PL) (1.4 MB - DOCX)

**First published:**

10/12/2025

[View](/pl/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_pl.docx)

português (PT) (692.19 KB - DOCX)

**First published:**

10/12/2025

[View](/pt/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_pt.docx)

română (RO) (800.12 KB - DOCX)

**First published:**

10/12/2025

[View](/ro/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_ro.docx)

slovenčina (SK) (806.51 KB - DOCX)

**First published:**

10/12/2025

[View](/sk/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_sk.docx)

slovenščina (SL) (759.34 KB - DOCX)

**First published:**

10/12/2025

[View](/sl/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_sl.docx)

Suomi (FI) (755.53 KB - DOCX)

**First published:**

10/12/2025

[View](/fi/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_fi.docx)

svenska (SV) (796.63 KB - DOCX)

**First published:**

10/12/2025

[View](/sv/documents/product-information-tracked-changes/livogiva-epar-product-information-tracked-changes_sv.docx)

#### Related content

- [Biosimilar medicines: Overview](/en/human-regulatory-overview/biosimilar-medicines-overview)

**This page was last updated on** 10/12/2025

## Share this page

[Back to top](#main-content)